Erytech Could Launch Several New Studies Following Pancreatic Cancer PhII Success

 
• By Lucie Ellis-Taitt
  
Cancer cells
Erytech's positive pancreatic cancer data could push the company towards other solid tumor indications
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D